


COPY OF PAPERS
ORIGINALLY FILED

Patent Docket No. E1777R1

Amend B/#10
5/15/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Devaux et al. Serial No.: 09/698,705 Filed: October 27, 2000 For: ANTI-TUMOR ANTIBODY COMPOSITIONS AND METHODS OF USE	Group Art Unit: 1642 Examiner: N. Davis RECEIVED MAY 10 2002 TECH CENTER 1600/2900 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, DC 20231 on April 23, 2002  Janet Tse
---	--

RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT

Commissioner of Patents and Trademarks
Washington, DC 20231

Sir:

This amendment is responsive to the Office Action mailed October 23, 2001, in connection with the above-identified application. A response to the Office Action was initially due on January 23, 2002. A Petition and fee authorization for a three (3) month extension of time are submitted herewith. Accordingly, this amendment is timely filed.

Reconsideration of the application is respectfully requested in view of the amendments and remarks submitted herein.

AMENDMENTS

In the claims:

Please amend claim 15 as follows:

BI DI
15. (Amended) An anti-PSCA monoclonal antibody that inhibits the growth of PSCA-expressing cancer cells in vivo, wherein the antibody internalizes upon binding to PSCA on the cancer cell.